Shenying Fang1, Dawen Sui1, Yuling Wang1, Huey Liu1, Yi-Ju Chiang1, Merrick I Ross1, Jeffrey E Gershenwald1, Janice N Cormier1, Richard E Royal1, Anthony Lucci1, Jennifer Wargo1, Mimi I Hu1, Julie M Gardner1, John D Reveille1, Roland L Bassett1, Qingyi Wei1, Christopher I Amos1, Jeffrey E Lee2. 1. Shenying Fang, Dawen Sui, Yuling Wang, Huey Liu, Yi-Ju Chiang, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Jennifer Wargo, Mimi I. Hu, Julie M. Gardner, Roland L. Bassett, and Jeffrey E. Lee, The University of Texas MD Anderson Cancer Center; John D. Reveille, The University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Dartmouth College, Lebanon, NH. 2. Shenying Fang, Dawen Sui, Yuling Wang, Huey Liu, Yi-Ju Chiang, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Jennifer Wargo, Mimi I. Hu, Julie M. Gardner, Roland L. Bassett, and Jeffrey E. Lee, The University of Texas MD Anderson Cancer Center; John D. Reveille, The University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Dartmouth College, Lebanon, NH jelee@mdanderson.org.
Abstract
PURPOSE: To evaluate for an association between 25-hydroxyvitamin D levels (vitamin D) and outcome measures in patients with melanoma after evaluation is controlled for systemic inflammatory response (SIR) on the basis of simultaneous C-reactive protein (CRP) measurement. MATERIALS AND METHODS: Plasma samples from 1,042 prospectively observed patients with melanoma were assayed for vitamin D and CRP. The associations of demographics and CRP with vitamin D were determined, followed by a determination of the association between vitamin D and stage and outcome measures from the date of blood draw. The vitamin D level was considered sufficient if it was 30 to 100 ng/mL. Kaplan-Meier and Cox regression analyses were performed. RESULTS: The median vitamin D level was 25.0 ng/mL. The median follow-up time was 7.1 years. A lower vitamin D was associated with the blood draw during fall/winter months (P < .001), older age (P = .001), increased CRP (P < .001), increased tumor thickness (P < .001), ulcerated tumor (P = .0105), and advanced melanoma stage (P = .0024). On univariate analysis, lower vitamin D was associated with poorer overall (OS; P < .001), melanoma-specific survival (MSS; P = .0025), and disease-free survival (DFS; P = .0466). The effect of vitamin D on these outcome measures persisted after adjustment for CRP and other covariates. Multivariable hazards ratios per unit decrease of vitamin D were 1.02 for OS (95% CI, 1.01 to 1.04; P = .0051), 1.02 for MSS (95% CI, 1.00 to 1.04; P = .048), and 1.02 for DFS (95% CI, 1.00 to 1.04; P = .0427). CONCLUSION:Lower vitamin D levels in patients with melanoma were associated with poorer outcomes. Although lower vitamin D was strongly associated with higher CRP, the associations of lower vitamin D with poorer OS, MSS, and DFS were independent of this association. Investigation of mechanisms responsible for these associations may be of value to patients with melanoma.
RCT Entities:
PURPOSE: To evaluate for an association between 25-hydroxyvitamin D levels (vitamin D) and outcome measures in patients with melanoma after evaluation is controlled for systemic inflammatory response (SIR) on the basis of simultaneous C-reactive protein (CRP) measurement. MATERIALS AND METHODS: Plasma samples from 1,042 prospectively observed patients with melanoma were assayed for vitamin D and CRP. The associations of demographics and CRP with vitamin D were determined, followed by a determination of the association between vitamin D and stage and outcome measures from the date of blood draw. The vitamin D level was considered sufficient if it was 30 to 100 ng/mL. Kaplan-Meier and Cox regression analyses were performed. RESULTS: The median vitamin D level was 25.0 ng/mL. The median follow-up time was 7.1 years. A lower vitamin D was associated with the blood draw during fall/winter months (P < .001), older age (P = .001), increased CRP (P < .001), increased tumor thickness (P < .001), ulcerated tumor (P = .0105), and advanced melanoma stage (P = .0024). On univariate analysis, lower vitamin D was associated with poorer overall (OS; P < .001), melanoma-specific survival (MSS; P = .0025), and disease-free survival (DFS; P = .0466). The effect of vitamin D on these outcome measures persisted after adjustment for CRP and other covariates. Multivariable hazards ratios per unit decrease of vitamin D were 1.02 for OS (95% CI, 1.01 to 1.04; P = .0051), 1.02 for MSS (95% CI, 1.00 to 1.04; P = .048), and 1.02 for DFS (95% CI, 1.00 to 1.04; P = .0427). CONCLUSION: Lower vitamin D levels in patients with melanoma were associated with poorer outcomes. Although lower vitamin D was strongly associated with higher CRP, the associations of lower vitamin D with poorer OS, MSS, and DFS were independent of this association. Investigation of mechanisms responsible for these associations may be of value to patients with melanoma.
Authors: Jennifer L Kelly; Gilles Salles; Bryan Goldman; Richard I Fisher; Pauline Brice; Oliver Press; Olivier Casasnovas; David G Maloney; Pierre Soubeyran; Lisa Rimsza; Corinne Haioun; Luc Xerri; Michael LeBlanc; Hervé Tilly; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-03-30 Impact factor: 44.544
Authors: Heike A Bischoff-Ferrari; Edward Giovannucci; Walter C Willett; Thomas Dietrich; Bess Dawson-Hughes Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: Andrew Duncan; Dinesh Talwar; Donald C McMillan; Fiona Stefanowicz; Denis St J O'Reilly Journal: Am J Clin Nutr Date: 2011-12-07 Impact factor: 7.045
Authors: Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets Journal: Lab Invest Date: 2017-02-20 Impact factor: 5.662
Authors: Leonardo Campiotti; Elena Bolzacchini; Matteo Basilio Sutter; Andrea Maria Maresca; Anna Maria Grandi; Luigina Guasti Journal: Intern Emerg Med Date: 2018-09-25 Impact factor: 3.397
Authors: Stephanie J Weinstein; Alison M Mondul; Kai Yu; Tracy M Layne; Christian C Abnet; Neal D Freedman; Racheal Z Stolzenberg-Solomon; Unhee Lim; Mitchell H Gail; Demetrius Albanes Journal: Eur J Epidemiol Date: 2018-08-02 Impact factor: 8.082
Authors: Irene Orlow; Yang Shi; Peter A Kanetsky; Nancy E Thomas; Li Luo; Sergio Corrales-Guerrero; Anne E Cust; Lidia Sacchetto; Roberto Zanetti; Stefano Rosso; Bruce K Armstrong; Terence Dwyer; Alison Venn; Richard P Gallagher; Stephen B Gruber; Loraine D Marrett; Hoda Anton-Culver; Klaus Busam; Colin B Begg; Marianne Berwick Journal: Pigment Cell Melanoma Res Date: 2017-11-05 Impact factor: 4.693